The majority of all US-based clinical trials have traditionally moved sequentially from one phase to the next. In the intricate world of drug development, the transition from Phase II to Phase III clinical trials is a pivotal juncture, often likened to a marathon runner approaching the final stretch. The finish line is in sight, but several hurdles are still left to overcome.
In 2016, the Biotechnology Innovation Organization (BIO) published a report that provided success rates for clinical drug development. According to that report, the overall likelihood of a Phase II clinical trial advancing to Phase III was approximately between 30-40%. With ever-increasing costs, the challenges of recruiting principal investigators, doctors, and patients, the delays often experienced in gaining regulatory approvals, and the need to bring new and innovative classes of therapeutics to market more quickly and often, the concept of parallel clinical trial sequencing has emerged.
Parallel sequencing is an approach that merges the boundaries between different phases of drug development by simultaneous planning and potential overlapping execution of two consequential phases of the trial. Rather than waiting for the completion of Phase II, the teams may start designing and preparing for Phase III well before their Phase II portion of the trial is complete, thereby enabling a seamless transition if Phase II shows promising results. In parallel sequencing, the planning and execution of Phase II (which often assesses the efficacy of a new treatment) and Phase III (which confirms efficacy in much larger populations) can occur simultaneously to some extent.
While this is not a new concept in the development and the management of Pharmaceutical clinical trials, when considered for use between Phase II and Phase III clinical trials, it may improve the overall effectiveness of a trial’s resource utilization, reduce a new drug’s time to market, and more.
Potential benefits of Phase II to Phase III clinical trial parallel sequencing
- Higher potential for ROI. Successfully moving from Phase II to Phase III indicates that the drug or treatment has shown promise in earlier trials. This can lead to increased investor confidence and potentially higher returns on investment once the drug is commercialized.
- Increased market confidence. Demonstrating efficacy and safety in Phase II trials and progressing to Phase III can boost the confidence of key investors and shareholders.
- Early market entry. Parallel sequencing can expedite the drug development process. Faster progression means that the drug can potentially enter the market sooner, giving the company a competitive advantage.
- New partnerships and licensing deals. Positive results and the progression to Phase III can attract potential partners for co-development or licensing deals. These partnerships can bring in upfront payments, milestone payments, and royalties once the drug is commercialized.
- Increased company valuation. Advancing to Phase III trials can significantly increase the valuation of a biotech or pharmaceutical company, making it an attractive target for mergers and acquisitions.
- Expanded opportunities. If the drug shows promise in its primary indication during Phase II, there might be potential to explore other indications, leading to expanded market opportunities.
- Data monetization. The vast amount of data generated from parallel sequencing can be monetized. Companies can sell this data (while maintaining patient privacy) to other research institutions or use it to fuel further internal research.
- Cost efficiency. While parallel sequencing might have higher upfront costs, the simultaneous progression can lead to cost savings in the long run. Overlapping phases can reduce the total time to market, and time is money in the drug development world.
- Positive public relations. Advancing to Phase III can generate positive media coverage, enhancing the company's reputation in the industry and with the general public.
- Potential for breakthrough therapy designation. If the drug shows significant improvement over existing treatments in Phase II, it might qualify for the Breakthrough Therapy Designation by regulatory agencies. This can expedite the review process and bring the drug to market even faster.
Considerations before leveraging parallel sequencing
Experience has shown that adopting and implementing these newer clinical trial strategies has not been easy. The financial upsides are clear, but they come with associated risks that require careful mitigation.
Simultaneous planning and execution require a level of coordination, communication, and flexibility that may be new to many organizations. The technical benefits, such as innovative data management solutions, must be balanced against potential technical challenges if things do not proceed as planned.
If you’re weighing the benefits of parallel sequencing for an upcoming clinical trial, here are some key areas of focus to drive your organization’s initial planning conversations:
1
Goal Alignment
Successful parallel sequencing requires open collaboration and the identification of shared objectives across many functional areas, including clinical operations, data management, regulatory affairs, and more.
Sequencing is not just a matter of compressing timelines; it requires aligning goals early, sharing data quickly, and adjusting in real-time to emerging results.
2
Effective Commnunication
Sequencing also requires exceptionally close collaboration among investigators, statisticians, regulatory experts, and other stakeholders. Rigorous design, clear data-sharing agreements, and ongoing oversight will be needed to ensure that overlapping activities do not lead to confusion or errors.
Trial timelines often center on the availability of essential staff, who may have been already assigned to other clinical trial projects. Clarity from the beginning on resource availability, especially if sequencing phases, is critical to success.
3
Timeline Oversight
The duration of the transition from Phase II to Phase III trials varies widely, often spanning from a few months to several years. This timeline is influenced by myriad factors, from the results of the Phase II trials to the complexities inherent in the study design and the ever-stringent regulatory requirements.
The optimum timeframe for implementing parallel sequencing should be considered early in Phase II. Overlapping execution of Phase II and III will require careful orchestration of people, resources, milestones, and more. Done well, the total time to market for a new drug may be reduced. This can be critical in highly competitive therapeutic areas.
4
Financial Impacts
The financial aspect of sequencing phases is a double-edged sword. On the upside, time is money. The quicker a product progresses through the trials and reaches the market, the sooner it can start generating revenue. This expedited timeline can translate directly into substantial financial benefits, giving companies a competitive edge in the ever-evolving pharmaceutical landscape.
However, this acceleration is not without its potential pitfalls. The downside is the potential for increased costs due to simultaneous activities across phases. Moreover, if Phase II results are not favorable, the investments made in anticipation of Phase III become sunk costs, leading to significant financial losses.
Operationalizing a new clinical trial strategy
Parallel sequencing of Phase II to Phase III clinical trials represents a promising approach to accelerating drug development. By breaking down the traditional sequential barriers and allowing for overlapping planning and execution, substantial time savings may be achieved. However, optimum implementation requires a nuanced and adaptable approach. In some scenarios, parallel sequencing may offer substantial advantages; in others, the risks may outweigh the rewards.
Ultimately, the decision to pursue parallel sequencing should be based on a thorough analysis of the specific drug, the competitive landscape, the capabilities of the development team, and a clear-eyed assessment of the potential benefits and challenges. With the right planning and execution, parallel sequencing can be a powerful tool in the ongoing effort to bring new therapies to patients more quickly and efficiently.
RELATED SOLUTIONS
